Skip to main content
. 2023 Feb 23;14:1135952. doi: 10.3389/fphar.2023.1135952

FIGURE 3.

FIGURE 3

Withaferin A ameliorates steatosis and steatohepatitis both in vivo. (A,B) Representative images and graphs depicting a reduction in fat accumulation in the liver and liver weights in a withaferin A-treated WDSW-induced NAFLD mouse model. (C) Representative liver sections stained with hematoxylin-eosin (H&E) with a scale bar of 50 μM. (D) Relative mRNA expression levels of TNF-α, IL-6, IL-1β, and MCP1 were evaluated in the liver.